Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1448-1454

  Park, Jung Sun ^a   Sohn, Hyun Jung ^a   Park, Gyeong Sin ^b   Chung, Yeun Jun ^a   Kim, Tai Gyu ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MESSENGER RNA; POLO LIKE KINASE 1;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ELECTROPORATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION; TUMOR IMMUNITY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DENDRITIC CELLS; ELECTROPORATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 79960398656     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01974.x     Document Type: Article

References (40)

1. Lowery DM, Lim D, Yaffe MB. Structure and function of Polo-like kinases. Oncogene 2005; 24: 248-59.
2. van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle 2006; 5: 853-64.
3. Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis: cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008; 20: 650-60.
4. Clay FJ, McEwen SJ, Bertoncello I, Wilks AF, Dunn AR. Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc Natl Acad Sci U S A 1993; 90: 4882-6.
5. Hamanaka R, Maloid S, Smith MR, O'Connell CD, Longo DL, Ferris DK. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ 1994; 5: 249-57.
6. Smith MR, Wilson ML, Hamanaka R et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234: 397-405.
7. Takai N, Hamanaka R, Yoshimatsu J et al. Polo-like kinases (Plks) and cancer. Oncogene 2005; 24: 287-91.
8. Loddo M, Kingsbury SR, Rashid M et al. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 2009; 100: 959-70.
9. Kanaji S, Saito H, Tsujitani S et al. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006; 70: 126-33.
10. Schmit TL, Zhong W, Nihal M, Ahmad N. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 2009; 8: 2697-702.
11. Weichert W, Denkert C, Schmidt M et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90: 815-21.
12. Takahashi T, Sano B, Nagata T et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148-52.
13. He ZL, Zheng H, Lin H, Miao XY, Zhong DW. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 2009; 15: 4177-82.
14. Ikezoe T, Yang J, Nishioka C et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009; 23: 1564-76.
15. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26: 2093-108.
16. Judge AD, Robbins M, Tavakoli I et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119: 661-73.
17. Guan R, Tapang P, Leverson JD et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65: 2698-704.
18. Gumireddy K, Reddy MV, Cosenza SC et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7: 275-86.
19. Steegmaier M, Hoffmann M, Baum A et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-22.
20. Garland LL, Taylor C, Pilkington DL et al. A Phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 2006; 12: 5182-9.
21. Chopra P, Sethi G, Dastidar SG et al. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010; 19: 27-43.
22. Park SD, Kim CH, Kim CK et al. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 2007; 25: 3485-91.
23. Kim CH, Yoon JS, Sohn HJ et al. Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model. Cancer Lett 2007; 250: 276-83.
24. Park JS, Kim HS, Park MY et al. Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope. Cancer Immunol Immunother 2010; 59: 747-57.
25. Nair SK, Boczkowski D, Morse M et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16: 364-9.
26. Ochi T, Fujiwara H, Suemori K et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009; 113: 66-74.
27. Yokomine K, Senju S, Nakatsura T et al. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer 2010; 126: 2153-63.
28. Li F, Yang D, Wang Y. Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen. Cancer Immunol Immunother 2009; 58: 2039-49.
29. Fu Z, Malureanu L, Huang J et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol 2008; 10: 1076-82.
30. Macurek L, Lindqvist A, Lim D et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008; 455: 119-23.
31. Feng Y, Yuan JH, Maloid SC et al. Polo-like kinase 1-mediated phosphorylation of the GTP-binding protein Ran is important for bipolar spindle formation. Biochem Biophys Res Commun 2006; 349: 144-52.
32. Li H, Wang Y, Liu X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem 2008; 283: 6209-21.
33. Moon Y, Park G, Han K et al. Mouse spleen tissue as a staining intensity reference for immunohistochemistry. Ann Clin Lab Sci 2008; 38: 215-20.
34. + T cells. Vaccine 2008; 26: 3987-97.
35. Nagaraj S, Pisarev V, Kinarsky L et al. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 2007; 30: 169-79.
36. + regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007; 98: 416-23.
37. Steitz J, Bruck J, Steinbrink K et al. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 2000; 86: 89-94.
38. Gold JS, Ferrone CR, Guevara-Patino JA et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003; 170: 5188-94.
39. Mamula MJ, Lin RH, Janeway CA et al. Breaking T cell tolerance with foreign and self co-immunogens A study of autoimmune B and T cell epitopes of cytochrome c. J Immunol 1992; 149: 789-95.
40. Kim HS, Kim CH, Park MY et al. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model. Immunol Lett 2010; 131: 73-80.